Shanghai Xiao Fang Pharmaceutical Co.,Ltd. (SHA:603207)

SHA:603207 Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	721.47	647.59	883.43	285.54	58.66	44.81
Short-Term Investments	-	-	-	-	1.31	5.08
Trading Asset Securities	-	-	-	2.97	108.96	158.11
Cash & Short-Term Investments	721.47	647.59	883.43	288.52	168.93	208.01
Cash Growth	-1.82%	-26.70%	206.20%	70.79%	-18.79%	84.58%
Accounts Receivable	111.37	123.97	90.29	85.39	81.88	55.82
Other Receivables	0.51	2.93	2.21	2.06	0.82	0.72
Receivables	111.88	126.9	92.5	87.46	82.69	56.55
Inventory	56.5	69.18	45.21	49.9	57.2	53.37
Other Current Assets	11.98	16.19	10.8	26.19	19.04	8.45
Total Current Assets	901.83	859.86	1,032	452.06	327.87	326.37
Property, Plant & Equipment	358.74	349.22	338.04	226.57	62.97	25.75
Long-Term Investments	-	-	-	-	-	1.27
Other Intangible Assets	21.75	22.94	24.53	26.12	27.7	29.23
Long-Term Deferred Tax Assets	6.32	4.8	3.36	2.86	2.27	2
Long-Term Deferred Charges	0.15	-	1.32	0.47	0.49	0.74
Other Long-Term Assets	17.73	2.65	3.26	4.58	42	0.67
Total Assets	1,307	1,239	1,402	712.65	463.3	386.02

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	28.11	38.99	23.09	19.61	27.42	16.61
Accrued Expenses	6.96	37.08	36.34	38.38	28.91	34.34
Short-Term Debt	3.76	1.12	1.65	-	-	-
Current Portion of Leases	-	1.06	0.67	0.42	-	-
Current Income Taxes Payable	12.27	6.09	7.13	5.33	12.5	13.71
Current Unearned Revenue	0.73	6.97	0.89	0.61	1.55	11.79
Other Current Liabilities	119.98	55.02	98.38	67.82	19.58	79.09
Total Current Liabilities	173.59	146.34	168.15	132.18	89.96	155.55
Long-Term Leases	-	0.32	-	0.44	0.88	1.27
Long-Term Unearned Revenue	0.04	0.05	0.07	0.08	0.09	0.1
Total Liabilities	173.63	146.71	168.21	132.7	90.94	156.92

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	161.78	160.56	160	120	120	120
Additional Paid-In Capital	506.28	489.09	478.23	69.22	65.25	61.18
Retained Earnings	483.27	450.26	596.01	390.73	187.11	47.93
Treasury Stock	-18.44	-7.15	-	-	-	-
Shareholders' Equity	1,133	1,093	1,234	579.95	372.36	229.11
Total Liabilities & Equity	1,307	1,239	1,402	712.65	463.3	386.02

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	5.55	2.5	2.32	0.86	0.88	1.27
Net Cash (Debt)	715.92	645.08	881.11	287.65	168.05	206.74
Net Cash Growth	-2.34%	-26.79%	206.31%	71.17%	-18.71%	83.45%
Net Cash Per Share	4.41	4.01	6.57	2.40	1.40	1.72
Filing Date Shares Outstanding	166.25	160.82	160.56	160	120	120
Total Common Shares Outstanding	166.25	160.56	160	120	120	120
Working Capital	728.24	713.52	863.79	319.89	237.9	170.83
Book Value Per Share	6.81	6.81	7.71	4.83	3.10	1.91
Tangible Book Value	1,111	1,070	1,210	553.84	344.66	199.88
Tangible Book Value Per Share	6.68	6.66	7.56	4.62	2.87	1.67
Buildings	-	13.22	26.35	26.35	26.35	25.62
Machinery	-	41	36.94	35.52	35.19	32.62
Construction In Progress	-	336.51	329.17	216.53	50.04	12.67

Data Source: S&P Global Market Intelligence Last updated: Oct 13, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 24, 2026

Data Sources Report a data error